Literature DB >> 6967875

Vitamin D metabolism in hypoparathyroidism.

B Lund, O H Sørensen, B Lund, J E Bishop, A W Norman.   

Abstract

Only moderately reduced serum 1,25-dihydroxyvitamin D [1,25(OH)2D3] levels were found in 13 hypoparathyroid patients and in 1 pseudohypoparathyroid patient, indicating that factors other than parathyroid hormone are able to mediate the basal production of 1,25(OH)2D3. A significant correlation was found between the levels of circulating 25-hydroxyvitamin D (25OHD) and 1,25(OH)2D, suggesting that a high concentration of 25OHD was able to increase the renal production of 1,25(OH)2D, whereas hypocalcemia and changes in serum phosphate became less important in the present situation. The serum 25OHD and 1,25(OH)2D concentrations were followed during the change of treatment from ergocalciferol to 1 alpha-hydroxycholecalciferol (1 alpha-OHD3). A biological half-life of 3 weeks could be estimated for the plasma 25OHD. The increase in serum 1,25(OH)2D correlated with the dose of 1 alpha-OHD3 given, whereas no correlation was found between the serum calcium level and the 1,25(OH)2D concentration. Unexpected increases and decreases in serum calcium were observed at the same dose of 1 alpha-OHD3 in the same patient and at serum 1,25(OH)2D concentrations within the physiological range.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967875     DOI: 10.1210/jcem-51-3-606

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Vitamin D-endocrine system.

Authors:  N H Bell
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

2.  Hypercalcaemic sarcoidosis in hypoparathyroidism.

Authors:  T H Mitchell; T C Stamp; M V Jenkins; E B Mawer; J L Berry
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

3.  Increased 1,25-dihydroxyvitamin D in patients with generalized scleroderma and no aberrant calcifications.

Authors:  J Serup; H K Hagdrup
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

4.  Response of plasma 1,25-dihydroxyvitamin D in the human PTH(1-34) infusion test: an improved index for the diagnosis of idiopathic hypoparathyroidism and pseudohypoparathyroidism.

Authors:  R Miura; S Yumita; K Yoshinaga; Y Furukawa
Journal:  Calcif Tissue Int       Date:  1990-05       Impact factor: 4.333

5.  Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism.

Authors:  K Mizunashi; Y Furukawa; R Miura; S Yumita; H E Sohn; K Yoshinaga
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

6.  Evidence for extrarenal production of 1 alpha ,25-dihydroxyvitamin D in man.

Authors:  P W Lambert; P H Stern; R C Avioli; N C Brackett; R T Turner; A Greene; I Y Fu; N H Bell
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

7.  25-Hydroxyvitamin D3 induces osteogenic differentiation of human mesenchymal stem cells.

Authors:  Yan-Ru Lou; Tai Chong Toh; Yee Han Tee; Hanry Yu
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

8.  Vitamin D and hyperparathyroidism: the Lumleian Lecture 1981.

Authors:  S W Stanbury
Journal:  J R Coll Physicians Lond       Date:  1981-10

9.  Without 1α-hydroxylation, the gene expression profile of 25(OH)D3 treatment overlaps deeply with that of 1,25(OH)2D3 in prostate cancer cells.

Authors:  Takao Susa; Masayoshi Iizuka; Hiroko Okinaga; Mimi Tamamori-Adachi; Tomoki Okazaki
Journal:  Sci Rep       Date:  2018-06-13       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.